Abaloparatide is used for: Osteoporosis

Adult Dose

Osteoporosis Indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy In postmenopausal women with osteoporosis, clinical trials showed abaloparatide reduces the risk of vertebral fractures and nonvertebral fractures 80 mcg SC qDay

Child Dose

Renal Dose


SC Preparation Clear and colorless solution Visually inspect for particulate matter and discoloration prior to administration Do not use if solid particles appear or if the solution is cloudy or colored Provide appropriate training and instruction to patients and caregivers on the proper use of the pen SC Administration Administer as a SC injection into the periumbilical region of the abdomen Rotate the site of the injection every day and administer at approximately the same time every day Do not administer IV or IM Administer the first several doses where the patient can sit or lie down if necessary, in case symptoms of orthostatic hypotension occur

Contra Indications


Dose-dependent increase in incidence of osteosarcoma in rats observed May cause orthostatic hypotension, typically within 4 hr after injection; instruct patient to sit or lie down for the first several doses if necessary May cause hypercalcemia; not recommended with preexisting hypercalcemia or in patients who have an underlying hypercalcemic disorder (eg, primary hyperparathyroidism) because of the possibility of exacerbating hypercalcemia May cause hypercalciuria; unknown whether the drug may exacerbate urolithiasis in patients with active or a history of urolithiasis; if active urolithiasis or preexisting hypercalciuria is suspected, measurement of urinary calcium excretion should be considered


Pregnancy Not indicated for females of reproductive potential Lactation Not indicated for females of reproductive potential


Adverse Effects

Side effects of Abaloparatide : >10% Injection site redness (58%) Hypercalciuria (11%) 1-10% Dizziness (10%) Injection site edema (10%) Nausea (8%) Headache (8%) Palpitations (5%) Orthostatic hypotension (4%) Fatigue (3%) Upper abdominal pain (3%) Hypercalcemia (3%) Vertigo (2%) Tachycardia (2%)

Mechanism of Action

Synthetic peptide analog of human parathyroid hormone-related protein (hPTHrP); hPTHrP is a naturally occurring hormone that, among other functions, regulates bone formation Elicits anabolic effect on bone, demonstrated by increases in bone mineral density and content that correlated with increases in bone strength at vertebral and/or nonvertebral sites